Antibiotic Resistance Market Size, Share & Trends Report

Antibiotic Resistance Market Size, Share & Trends Analysis Report By Disease (BSI, CDI, cUTI, cIAI), By Pathogen (E. coli, P. Aeruginosa, K. Pneumoniae), By Drug Class, and Segment Forecasts, 2018 - 2025

  • Published Date: Dec 2018
  • Report ID: GVR-2-68038-663-9
  • Number of Pages: 120
  • Format: Electronic (PDF)
  • Historical Data:

Market Segmentation

  • Antibiotic Resistance Disease Outlook (Revenue, USD Billion, 2014 - 2025)
    • Complicated Urinary Tract Infection (cUTI)
    • Complicated Intra-Abdominal Infections (cIAI)
    • Blood Stream Infections (BSI)
    • Clostridium difficile infections (CDI)
    • Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
    • Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
    • Community Acquired Bacterial Pneumonia (CABP)
  • Antibiotic Resistance Pathogen Outlook (Revenue, USD Billion, 2014 - 2025)
    • Acinetobacter baumannii (Carbapenem-Resistant)
    • Pseudomonas aeruginosa (Carbapenem-Resistant)
    • Staphylococcus Aureus (Methicillin-Resistant)
    • E. coli/K. pneumoniae (Carbapenem-Resistant)
    • Streptococcus pneumoniae (Penicillin-Non-Susceptible)
    • Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
    • Enterococcus faecium (Vancomycin-Resistant)
    • Haemophilus Influenzae (Ampicillin-Resistant)
  • Antibiotic Resistance Drug Class Outlook (Revenue, USD Billion, 2014 - 2025)
    • Oxazolidinones
    • Lipoglycopeptides
    • Tetracyclines
    • Cephalosporins
    • Combination
    • Others
  • Antibiotic-resistance Regional Outlook (Revenue, USD Billion, 2014 - 2025)
    • North America
      • North America Antibiotic Resistance Market, by Disease
        • Complicated Urinary Tract Infection (cUTI)
        • Complicated Intra-Abdominal Infections (cIAI)
        • Blood Stream Infections (BSI)
        • Clostridium difficile infections (CDI)
        • Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
        • Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
        • Community Acquired Bacterial Pneumonia (CABP)
      • North America Antibiotic Resistance Market, by Pathogen
        • Acinetobacter baumannii (Carbapenem-Resistant)
        • Staphylococcus Aureus (Methicillin-Resistant)
        • Pseudomonas aeruginosa (Carbapenem-Resistant)
        • E. coli/K. pneumoniae (Carbapenem-Resistant)
        • Enterococcus faecium (Vancomycin-Resistant)
        • Streptococcus pneumoniae (Penicillin-Non-Susceptible)
        • Haemophilus Influenzae (Ampicillin-Resistant)
        • Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
      • North America Antibiotic Resistance Market, by Drug Class
        • Oxazolidinones
        • Lipoglycopeptides
        • Tetracyclines
        • Cephalosporins
        • Combination
        • Others
      • The U.S. 
        • U.S. Antibiotic Resistance Market, by Disease
          • Complicated Urinary Tract Infection (cUTI)
          • Complicated Intra-Abdominal Infections (cIAI)
          • Blood Stream Infections (BSI)
          • Clostridium difficile infections (CDI)
          • Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
          • Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
          • Community Acquired Bacterial Pneumonia (CABP)
        • U.S. Antibiotic Resistance Market, by Pathogen
          • Acinetobacter baumannii (Carbapenem-Resistant)
          • Staphylococcus Aureus (Methicillin-Resistant)
          • Pseudomonas aeruginosa (Carbapenem-Resistant)
          • E. coli/K. pneumoniae (Carbapenem-Resistant)
          • Enterococcus faecium (Vancomycin-Resistant)
          • Streptococcus pneumoniae (Penicillin-Non-Susceptible)
          • Haemophilus Influenzae (Ampicillin-Resistant)
          • Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
        • U.S. Antibiotic Resistance Market, by Drug Class
          • Oxazolidinones
          • Lipoglycopeptides
          • Tetracyclines
          • Cephalosporins
          • Combination
          • Others
      • Canada 
        • Canada Antibiotic Resistance Market, by Disease
          • Complicated Urinary Tract Infection (cUTI)
          • Complicated Intra-Abdominal Infections (cIAI)
          • Blood Stream Infections (BSI)
          • Clostridium difficile infections (CDI)
          • Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
          • Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
          • Community Acquired Bacterial Pneumonia (CABP)
        • Canada Antibiotic Resistance Market, by Pathogen
          • Acinetobacter baumannii (Carbapenem-Resistant)
          • Staphylococcus Aureus (Methicillin-Resistant)
          • Pseudomonas aeruginosa (Carbapenem-Resistant)
          • E. coli/K. pneumoniae (Carbapenem-Resistant)
          • Enterococcus faecium (Vancomycin-Resistant)
          • Streptococcus pneumoniae (Penicillin-Non-Susceptible)
          • Haemophilus Influenzae (Ampicillin-Resistant)
          • Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
        • Canada Antibiotic Resistance Market, by Drug Class
          • Oxazolidinones
          • Lipoglycopeptides
          • Tetracyclines
          • Cephalosporins
          • Combination
          • Others
    • Europe
      • Europe Antibiotic Resistance Market, by Disease
        • Complicated Urinary Tract Infection (cUTI)
        • Complicated Intra-Abdominal Infections (cIAI)
        • Blood Stream Infections (BSI)
        • Clostridium difficile infections (CDI)
        • Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
        • Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
        • Community Acquired Bacterial Pneumonia (CABP)
      • Europe Antibiotic Resistance Market, by Pathogen
        • Acinetobacter baumannii (Carbapenem-Resistant)
        • Staphylococcus Aureus (Methicillin-Resistant)
        • Pseudomonas aeruginosa (Carbapenem-Resistant)
        • E. coli/K. pneumoniae (Carbapenem-Resistant)
        • Enterococcus faecium (Vancomycin-Resistant)
        • Streptococcus pneumoniae (Penicillin-Non-Susceptible)
        • Haemophilus Influenzae (Ampicillin-Resistant)
        • Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
      • Europe Antibiotic Resistance Market, by Drug Class
        • Oxazolidinones
        • Lipoglycopeptides
        • Tetracyclines
        • Cephalosporins
        • Combination
        • Others
      • The U.K.
        • U.K. Antibiotic Resistance Market, by Disease
          • Complicated Urinary Tract Infection (cUTI)
          • Complicated Intra-Abdominal Infections (cIAI)
          • Blood Stream Infections (BSI)
          • Clostridium difficile infections (CDI)
          • Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
          • Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
          • Community Acquired Bacterial Pneumonia (CABP)
        • U.K. Antibiotic Resistance Market, by Pathogen
          • Acinetobacter baumannii (Carbapenem-Resistant)
          • Staphylococcus Aureus (Methicillin-Resistant)
          • Pseudomonas aeruginosa (Carbapenem-Resistant)
          • E. coli/K. pneumoniae (Carbapenem-Resistant)
          • Enterococcus faecium (Vancomycin-Resistant)
          • Streptococcus pneumoniae (Penicillin-Non-Susceptible)
          • Haemophilus Influenzae (Ampicillin-Resistant)
          • Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
        • U.K. Antibiotic Resistance Market, by Drug Class
          • Oxazolidinones
          • Lipoglycopeptides
          • Tetracyclines
          • Cephalosporins
          • Combination
          • Others
      • Germany
        • Germany Antibiotic Resistance Market, by Disease
          • Complicated Urinary Tract Infection (cUTI)
          • Complicated Intra-Abdominal Infections (cIAI)
          • Blood Stream Infections (BSI)
          • Clostridium difficile infections (CDI)
          • Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
          • Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
          • Community Acquired Bacterial Pneumonia (CABP)
        • Germany Antibiotic Resistance Market, by Pathogen
          • Acinetobacter baumannii (Carbapenem-Resistant)
          • Staphylococcus Aureus (Methicillin-Resistant)
          • Pseudomonas aeruginosa (Carbapenem-Resistant)
          • E. coli/K. pneumoniae (Carbapenem-Resistant)
          • Enterococcus faecium (Vancomycin-Resistant)
          • Streptococcus pneumoniae (Penicillin-Non-Susceptible)
          • Haemophilus Influenzae (Ampicillin-Resistant)
          • Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
        • Germany Antibiotic Resistance Market, by Drug Class
          • Oxazolidinones
          • Lipoglycopeptides
          • Tetracyclines
          • Cephalosporins
          • Combination
          • Others
      • France
        • France Antibiotic Resistance Market, by Disease
          • Complicated Urinary Tract Infection (cUTI)
          • Complicated Intra-Abdominal Infections (cIAI)
          • Blood Stream Infections (BSI)
          • Clostridium difficile infections (CDI)
          • Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
          • Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
          • Community Acquired Bacterial Pneumonia (CABP)
        • France Antibiotic Resistance Market, by Pathogen
          • Acinetobacter baumannii (Carbapenem-Resistant)
          • Staphylococcus Aureus (Methicillin-Resistant)
          • Pseudomonas aeruginosa (Carbapenem-Resistant)
          • E. coli/K. pneumoniae (Carbapenem-Resistant)
          • Enterococcus faecium (Vancomycin-Resistant)
          • Streptococcus pneumoniae (Penicillin-Non-Susceptible)
          • Haemophilus Influenzae (Ampicillin-Resistant)
          • Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
        • France Antibiotic Resistance Market, by Drug Class
          • Oxazolidinones
          • Lipoglycopeptides
          • Tetracyclines
          • Cephalosporins
          • Combination
          • Others
      • Italy
        • Italy Antibiotic Resistance Market, by Disease
          • Complicated Urinary Tract Infection (cUTI)
          • Complicated Intra-Abdominal Infections (cIAI)
          • Blood Stream Infections (BSI)
          • Clostridium difficile infections (CDI)
          • Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
          • Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
          • Community Acquired Bacterial Pneumonia (CABP)
        • Italy Antibiotic Resistance Market, by Pathogen
          • Acinetobacter baumannii (Carbapenem-Resistant)
          • Staphylococcus Aureus (Methicillin-Resistant)
          • Pseudomonas aeruginosa (Carbapenem-Resistant)
          • E. coli/K. pneumoniae (Carbapenem-Resistant)
          • Enterococcus faecium (Vancomycin-Resistant)
          • Streptococcus pneumoniae (Penicillin-Non-Susceptible)
          • Haemophilus Influenzae (Ampicillin-Resistant)
          • Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
        • Italy Antibiotic Resistance Market, by Drug Class
          • Oxazolidinones
          • Lipoglycopeptides
          • Tetracyclines
          • Cephalosporins
          • Combination
          • Others
      • Spain
        • Spain Antibiotic Resistance Market, by Disease
          • Complicated Urinary Tract Infection (cUTI)
          • Complicated Intra-Abdominal Infections (cIAI)
          • Blood Stream Infections (BSI)
          • Clostridium difficile infections (CDI)
          • Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
          • Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
          • Community Acquired Bacterial Pneumonia (CABP)
        • Spain Antibiotic Resistance Market, by Pathogen
          • Acinetobacter baumannii (Carbapenem-Resistant)
          • Staphylococcus Aureus (Methicillin-Resistant)
          • Pseudomonas aeruginosa (Carbapenem-Resistant)
          • E. coli/K. pneumoniae (Carbapenem-Resistant)
          • Enterococcus faecium (Vancomycin-Resistant)
          • Streptococcus pneumoniae (Penicillin-Non-Susceptible)
          • Haemophilus Influenzae (Ampicillin-Resistant)
          • Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
        • Spain Antibiotic Resistance Market, by Drug Class
          • Oxazolidinones
          • Lipoglycopeptides
          • Tetracyclines
          • Cephalosporins
          • Combination
          • Others
      • Belgium
        • Belgium Antibiotic Resistance Market, by Disease
          • Complicated Urinary Tract Infection (cUTI)
          • Complicated Intra-Abdominal Infections (cIAI)
          • Blood Stream Infections (BSI)
          • Clostridium difficile infections (CDI)
          • Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
          • Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
          • Community Acquired Bacterial Pneumonia (CABP)
        • Belgium Antibiotic Resistance Market, by Pathogen
          • Acinetobacter baumannii (Carbapenem-Resistant)
          • Staphylococcus Aureus (Methicillin-Resistant)
          • Pseudomonas aeruginosa (Carbapenem-Resistant)
          • E. coli/K. pneumoniae (Carbapenem-Resistant)
          • Enterococcus faecium (Vancomycin-Resistant)
          • Streptococcus pneumoniae (Penicillin-Non-Susceptible)
          • Haemophilus Influenzae (Ampicillin-Resistant)
          • Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
        • Belgium Antibiotic Resistance Market, by Drug Class
          • Oxazolidinones
          • Lipoglycopeptides
          • Tetracyclines
          • Cephalosporins
          • Combination
          • Others
      • Greece
        • Greece Antibiotic Resistance Market, by Disease
          • Complicated Urinary Tract Infection (cUTI)
          • Complicated Intra-Abdominal Infections (cIAI)
          • Blood Stream Infections (BSI)
          • Clostridium difficile infections (CDI)
          • Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
          • Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
          • Community Acquired Bacterial Pneumonia (CABP)
        • Greece Antibiotic Resistance Market, by Pathogen
          • Acinetobacter baumannii (Carbapenem-Resistant)
          • Staphylococcus Aureus (Methicillin-Resistant)
          • Pseudomonas aeruginosa (Carbapenem-Resistant)
          • E. coli/K. pneumoniae (Carbapenem-Resistant)
          • Enterococcus faecium (Vancomycin-Resistant)
          • Streptococcus pneumoniae (Penicillin-Non-Susceptible)
          • Haemophilus Influenzae (Ampicillin-Resistant)
          • Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
        • Greece Antibiotic Resistance Market, by Drug Class
          • Oxazolidinones
          • Lipoglycopeptides
          • Tetracyclines
          • Cephalosporins
          • Combination
          • Others
      • Portugal
        • Portugal Antibiotic Resistance Market, by Disease
          • Complicated Urinary Tract Infection (cUTI)
          • Complicated Intra-Abdominal Infections (cIAI)
          • Blood Stream Infections (BSI)
          • Clostridium difficile infections (CDI)
          • Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
          • Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
          • Community Acquired Bacterial Pneumonia (CABP)
        • Portugal Antibiotic Resistance Market, by Pathogen
          • Acinetobacter baumannii (Carbapenem-Resistant)
          • Staphylococcus Aureus (Methicillin-Resistant)
          • Pseudomonas aeruginosa (Carbapenem-Resistant)
          • E. coli/K. pneumoniae (Carbapenem-Resistant)
          • Enterococcus faecium (Vancomycin-Resistant)
          • Streptococcus pneumoniae (Penicillin-Non-Susceptible)
          • Haemophilus Influenzae (Ampicillin-Resistant)
          • Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
        • Portugal Antibiotic Resistance Market, by Drug Class
          • Oxazolidinones
          • Lipoglycopeptides
          • Tetracyclines
          • Cephalosporins
          • Combination
          • Others
    • Asia Pacific
      • Asia Pacific Antibiotic Resistance Market, by Disease
        • Complicated Urinary Tract Infection (cUTI)
        • Complicated Intra-Abdominal Infections (cIAI)
        • Blood Stream Infections (BSI)
        • Clostridium difficile infections (CDI)
        • Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
        • Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
        • Community Acquired Bacterial Pneumonia (CABP)
      • Asia Pacific Antibiotic Resistance Market, by Pathogen
        • Acinetobacter baumannii (Carbapenem-Resistant)
        • Staphylococcus Aureus (Methicillin-Resistant)
        • Pseudomonas aeruginosa (Carbapenem-Resistant)
        • E. coli/K. pneumoniae (Carbapenem-Resistant)
        • Enterococcus faecium (Vancomycin-Resistant)
        • Streptococcus pneumoniae (Penicillin-Non-Susceptible)
        • Haemophilus Influenzae (Ampicillin-Resistant)
        • Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
      • Asia Pacific Antibiotic Resistance Market, by Drug Class
        • Oxazolidinones
        • Lipoglycopeptides
        • Tetracyclines
        • Cephalosporins
        • Combination
        • Others
      • Japan
        • Japan Antibiotic Resistance Market, by Disease
          • Complicated Urinary Tract Infection (cUTI)
          • Complicated Intra-Abdominal Infections (cIAI)
          • Blood Stream Infections (BSI)
          • Clostridium difficile infections (CDI)
          • Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
          • Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
          • Community Acquired Bacterial Pneumonia (CABP)
        • Japan Antibiotic Resistance Market, by Pathogen
          • Acinetobacter baumannii (Carbapenem-Resistant)
          • Staphylococcus Aureus (Methicillin-Resistant)
          • Pseudomonas aeruginosa (Carbapenem-Resistant)
          • E. coli/K. pneumoniae (Carbapenem-Resistant)
          • Enterococcus faecium (Vancomycin-Resistant)
          • Streptococcus pneumoniae (Penicillin-Non-Susceptible)
          • Haemophilus Influenzae (Ampicillin-Resistant)
          • Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
        • Japan Antibiotic Resistance Market, by Drug Class
          • Oxazolidinones
          • Lipoglycopeptides
          • Tetracyclines
          • Cephalosporins
          • Combination
          • Others
      • China
        • China Antibiotic Resistance Market, by Disease
          • Complicated Urinary Tract Infection (cUTI)
          • Complicated Intra-Abdominal Infections (cIAI)
          • Blood Stream Infections (BSI)
          • Clostridium difficile infections (CDI)
          • Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
          • Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
          • Community Acquired Bacterial Pneumonia (CABP)
        • China Antibiotic Resistance Market, by Pathogen
          • Acinetobacter baumannii (Carbapenem-Resistant)
          • Staphylococcus Aureus (Methicillin-Resistant)
          • Pseudomonas aeruginosa (Carbapenem-Resistant)
          • E. coli/K. pneumoniae (Carbapenem-Resistant)
          • Enterococcus faecium (Vancomycin-Resistant)
          • Streptococcus pneumoniae (Penicillin-Non-Susceptible)
          • Haemophilus Influenzae (Ampicillin-Resistant)
          • Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
        • China Antibiotic Resistance Market, by Drug Class
          • Oxazolidinones
          • Lipoglycopeptides
          • Tetracyclines
          • Cephalosporins
          • Combination
          • Others
      • India
        • India Antibiotic Resistance Market, by Disease
          • Complicated Urinary Tract Infection (cUTI)
          • Complicated Intra-Abdominal Infections (cIAI)
          • Blood Stream Infections (BSI)
          • Clostridium difficile infections (CDI)
          • Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
          • Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
          • Community Acquired Bacterial Pneumonia (CABP)
        • India Antibiotic Resistance Market, by Pathogen
          • Acinetobacter baumannii (Carbapenem-Resistant)
          • Staphylococcus Aureus (Methicillin-Resistant)
          • Pseudomonas aeruginosa (Carbapenem-Resistant)
          • E. coli/K. pneumoniae (Carbapenem-Resistant)
          • Enterococcus faecium (Vancomycin-Resistant)
          • Streptococcus pneumoniae (Penicillin-Non-Susceptible)
          • Haemophilus Influenzae (Ampicillin-Resistant)
          • Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
        • India Antibiotic Resistance Market, by Drug Class
          • Oxazolidinones
          • Lipoglycopeptides
          • Tetracyclines
          • Cephalosporins
          • Combination
          • Others
      • South Korea
        • South Korea Antibiotic Resistance Market, by Disease
          • Complicated Urinary Tract Infection (cUTI)
          • Complicated Intra-Abdominal Infections (cIAI)
          • Blood Stream Infections (BSI)
          • Clostridium difficile infections (CDI)
          • Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
          • Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
          • Community Acquired Bacterial Pneumonia (CABP)
        • South Korea Antibiotic Resistance Market, by Pathogen
          • Acinetobacter baumannii (Carbapenem-Resistant)
          • Staphylococcus Aureus (Methicillin-Resistant)
          • Pseudomonas aeruginosa (Carbapenem-Resistant)
          • E. coli/K. pneumoniae (Carbapenem-Resistant)
          • Enterococcus faecium (Vancomycin-Resistant)
          • Streptococcus pneumoniae (Penicillin-Non-Susceptible)
          • Haemophilus Influenzae (Ampicillin-Resistant)
          • Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
        • South Korea Antibiotic Resistance Market, by Drug Class
          • Oxazolidinones
          • Lipoglycopeptides
          • Tetracyclines
          • Cephalosporins
          • Combination
          • Others
      • Australia
        • Australia Antibiotic Resistance Market, by Disease
          • Complicated Urinary Tract Infection (cUTI)
          • Complicated Intra-Abdominal Infections (cIAI)
          • Blood Stream Infections (BSI)
          • Clostridium difficile infections (CDI)
          • Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
          • Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
          • Community Acquired Bacterial Pneumonia (CABP)
        • Australia Antibiotic Resistance Market, by Pathogen
          • Acinetobacter baumannii (Carbapenem-Resistant)
          • Staphylococcus Aureus (Methicillin-Resistant)
          • Pseudomonas aeruginosa (Carbapenem-Resistant)
          • E. coli/K. pneumoniae (Carbapenem-Resistant)
          • Enterococcus faecium (Vancomycin-Resistant)
          • Streptococcus pneumoniae (Penicillin-Non-Susceptible)
          • Haemophilus Influenzae (Ampicillin-Resistant)
          • Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
        • Australia Antibiotic Resistance Market, by Drug Class
          • Oxazolidinones
          • Lipoglycopeptides
          • Tetracyclines
          • Cephalosporins
          • Combination
          • Others
      • Hong Kong
        • Hong Kong Antibiotic Resistance Market, by Disease
          • Complicated Urinary Tract Infection (cUTI)
          • Complicated Intra-Abdominal Infections (cIAI)
          • Blood Stream Infections (BSI)
          • Clostridium difficile infections (CDI)
          • Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
          • Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
          • Community Acquired Bacterial Pneumonia (CABP)
        • Hong Kong Antibiotic Resistance Market, by Pathogen
          • Acinetobacter baumannii (Carbapenem-Resistant)
          • Staphylococcus Aureus (Methicillin-Resistant)
          • Pseudomonas aeruginosa (Carbapenem-Resistant)
          • E. coli/K. pneumoniae (Carbapenem-Resistant)
          • Enterococcus faecium (Vancomycin-Resistant)
          • Streptococcus pneumoniae (Penicillin-Non-Susceptible)
          • Haemophilus Influenzae (Ampicillin-Resistant)
          • Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
        • Hong Kong Antibiotic Resistance Market, by Drug Class
          • Oxazolidinones
          • Lipoglycopeptides
          • Tetracyclines
          • Cephalosporins
          • Combination
          • Others
      • Singapore
        • Singapore Antibiotic Resistance Market, by Disease
          • Complicated Urinary Tract Infection (cUTI)
          • Complicated Intra-Abdominal Infections (cIAI)
          • Blood Stream Infections (BSI)
          • Clostridium difficile infections (CDI)
          • Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
          • Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
          • Community Acquired Bacterial Pneumonia (CABP)
        • Singapore Antibiotic Resistance Market, by Pathogen
          • Acinetobacter baumannii (Carbapenem-Resistant)
          • Staphylococcus Aureus (Methicillin-Resistant)
          • Pseudomonas aeruginosa (Carbapenem-Resistant)
          • E. coli/K. pneumoniae (Carbapenem-Resistant)
          • Enterococcus faecium (Vancomycin-Resistant)
          • Streptococcus pneumoniae (Penicillin-Non-Susceptible)
          • Haemophilus Influenzae (Ampicillin-Resistant)
          • Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
        • Singapore Antibiotic Resistance Market, by Drug Class
          • Oxazolidinones
          • Lipoglycopeptides
          • Tetracyclines
          • Cephalosporins
          • Combination
          • Others
      • Taiwan
        • Taiwan Antibiotic Resistance Market, by Disease
          • Complicated Urinary Tract Infection (cUTI)
          • Complicated Intra-Abdominal Infections (cIAI)
          • Blood Stream Infections (BSI)
          • Clostridium difficile infections (CDI)
          • Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
          • Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
          • Community Acquired Bacterial Pneumonia (CABP)
        • Taiwan Antibiotic Resistance Market, by Pathogen
          • Acinetobacter baumannii (Carbapenem-Resistant)
          • Staphylococcus Aureus (Methicillin-Resistant)
          • Pseudomonas aeruginosa (Carbapenem-Resistant)
          • E. coli/K. pneumoniae (Carbapenem-Resistant)
          • Enterococcus faecium (Vancomycin-Resistant)
          • Streptococcus pneumoniae (Penicillin-Non-Susceptible)
          • Haemophilus Influenzae (Ampicillin-Resistant)
          • Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
        • Taiwan Antibiotic Resistance Market, by Drug Class
          • Oxazolidinones
          • Lipoglycopeptides
          • Tetracyclines
          • Cephalosporins
          • Combination
          • Others
    • Latin America
      • Latin America Antibiotic Resistance Market, by Disease
        • Complicated Urinary Tract Infection (cUTI)
        • Complicated Intra-Abdominal Infections (cIAI)
        • Blood Stream Infections (BSI)
        • Clostridium difficile infections (CDI)
        • Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
        • Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
        • Community Acquired Bacterial Pneumonia (CABP)
      • Latin America  Antibiotic Resistance Market, by Pathogen
        • Acinetobacter baumannii (Carbapenem-Resistant)
        • Staphylococcus Aureus (Methicillin-Resistant)
        • Pseudomonas aeruginosa (Carbapenem-Resistant)
        • E. coli/K. pneumoniae (Carbapenem-Resistant)
        • Enterococcus faecium (Vancomycin-Resistant)
        • Streptococcus pneumoniae (Penicillin-Non-Susceptible)
        • Haemophilus Influenzae (Ampicillin-Resistant)
        • Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
      • Latin America Antibiotic Resistance Market, by Drug Class
        • Oxazolidinones
        • Lipoglycopeptides
        • Tetracyclines
        • Cephalosporins
        • Combination
        • Others
      • Brazil
        • Brazil Antibiotic Resistance Market, by Disease
          • Complicated Urinary Tract Infection (cUTI)
          • Complicated Intra-Abdominal Infections (cIAI)
          • Blood Stream Infections (BSI)
          • Clostridium difficile infections (CDI)
          • Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
          • Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
          • Community Acquired Bacterial Pneumonia (CABP)
        • Brazil Antibiotic Resistance Market, by Pathogen
          • Acinetobacter baumannii (Carbapenem-Resistant)
          • Staphylococcus Aureus (Methicillin-Resistant)
          • Pseudomonas aeruginosa (Carbapenem-Resistant)
          • E. coli/K. pneumoniae (Carbapenem-Resistant)
          • Enterococcus faecium (Vancomycin-Resistant)
          • Streptococcus pneumoniae (Penicillin-Non-Susceptible)
          • Haemophilus Influenzae (Ampicillin-Resistant)
          • Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
        • Brazil Antibiotic Resistance Market, by Drug Class
          • Oxazolidinones
          • Lipoglycopeptides
          • Tetracyclines
          • Cephalosporins
          • Combination
          • Others
      • Mexico
        • Mexico Antibiotic Resistance Market, by Disease
          • Complicated Urinary Tract Infection (cUTI)
          • Complicated Intra-Abdominal Infections (cIAI)
          • Blood Stream Infections (BSI)
          • Clostridium difficile infections (CDI)
          • Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
          • Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
          • Community Acquired Bacterial Pneumonia (CABP)
        • Mexico Antibiotic Resistance Market, by Pathogen
          • Acinetobacter baumannii (Carbapenem-Resistant)
          • Staphylococcus Aureus (Methicillin-Resistant)
          • Pseudomonas aeruginosa (Carbapenem-Resistant)
          • E. coli/K. pneumoniae (Carbapenem-Resistant)
          • Enterococcus faecium (Vancomycin-Resistant)
          • Streptococcus pneumoniae (Penicillin-Non-Susceptible)
          • Haemophilus Influenzae (Ampicillin-Resistant)
          • Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
        • Mexico Antibiotic Resistance Market, by Drug Class
          • Oxazolidinones
          • Lipoglycopeptides
          • Tetracyclines
          • Cephalosporins
          • Combination
          • Others
      • Argentina
        • Argentina Antibiotic Resistance Market, by Disease
          • Complicated Urinary Tract Infection (cUTI)
          • Complicated Intra-Abdominal Infections (cIAI)
          • Blood Stream Infections (BSI)
          • Clostridium difficile infections (CDI)
          • Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
          • Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
          • Community Acquired Bacterial Pneumonia (CABP)
        • Argentina Antibiotic Resistance Market, by Pathogen
          • Acinetobacter baumannii (Carbapenem-Resistant)
          • Staphylococcus Aureus (Methicillin-Resistant)
          • Pseudomonas aeruginosa (Carbapenem-Resistant)
          • E. coli/K. pneumoniae (Carbapenem-Resistant)
          • Enterococcus faecium (Vancomycin-Resistant)
          • Streptococcus pneumoniae (Penicillin-Non-Susceptible)
          • Haemophilus Influenzae (Ampicillin-Resistant)
          • Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
        • Argentina Antibiotic Resistance Market, by Drug Class
          • Oxazolidinones
          • Lipoglycopeptides
          • Tetracyclines
          • Cephalosporins
          • Combination
          • Others
    • Middle East and Africa
      • Middle East and Africa Antibiotic Resistance Market, by Disease
        • Complicated Urinary Tract Infection (cUTI)
        • Complicated Intra-Abdominal Infections (cIAI)
        • Blood Stream Infections (BSI)
        • Clostridium difficile infections (CDI)
        • Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
        • Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
        • Community Acquired Bacterial Pneumonia (CABP)
      • Middle East and Africa Antibiotic Resistance Market, by Pathogen
        • Acinetobacter baumannii (Carbapenem-Resistant)
        • Staphylococcus Aureus (Methicillin-Resistant)
        • Pseudomonas aeruginosa (Carbapenem-Resistant)
        • E. coli/K. pneumoniae (Carbapenem-Resistant)
        • Enterococcus faecium (Vancomycin-Resistant)
        • Streptococcus pneumoniae (Penicillin-Non-Susceptible)
        • Haemophilus Influenzae (Ampicillin-Resistant)
        • Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
      • Middle East and Africa Antibiotic Resistance Market, by Drug Class
        • Oxazolidinones
        • Lipoglycopeptides
        • Tetracyclines
        • Cephalosporins
        • Combination
        • Others
      • South Africa
        • South Africa Antibiotic Resistance Market, by Disease
          • Complicated Urinary Tract Infection (cUTI)
          • Complicated Intra-Abdominal Infections (cIAI)
          • Blood Stream Infections (BSI)
          • Clostridium difficile infections (CDI)
          • Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
          • Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
          • Community Acquired Bacterial Pneumonia (CABP)
        • South Africa Antibiotic Resistance Market, by Pathogen
          • Acinetobacter baumannii (Carbapenem-Resistant)
          • Staphylococcus Aureus (Methicillin-Resistant)
          • Pseudomonas aeruginosa (Carbapenem-Resistant)
          • E. coli/K. pneumoniae (Carbapenem-Resistant)
          • Enterococcus faecium (Vancomycin-Resistant)
          • Streptococcus pneumoniae (Penicillin-Non-Susceptible)
          • Haemophilus Influenzae (Ampicillin-Resistant)
          • Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
        • South Africa Antibiotic Resistance Market, by Drug Class
          • Oxazolidinones
          • Lipoglycopeptides
          • Tetracyclines
          • Cephalosporins
          • Combination
          • Others
      • Saudi Arabia
        • Saudi Arabia Antibiotic Resistance Market, by Disease
          • Complicated Urinary Tract Infection (cUTI)
          • Complicated Intra-Abdominal Infections (cIAI)
          • Blood Stream Infections (BSI)
          • Clostridium difficile infections (CDI)
          • Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
          • Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
          • Community Acquired Bacterial Pneumonia (CABP)
        • Saudi Arabia Antibiotic Resistance Market, by Pathogen
          • Acinetobacter baumannii (Carbapenem-Resistant)
          • Staphylococcus Aureus (Methicillin-Resistant)
          • Pseudomonas aeruginosa (Carbapenem-Resistant)
          • E. coli/K. pneumoniae (Carbapenem-Resistant)
          • Enterococcus faecium (Vancomycin-Resistant)
          • Streptococcus pneumoniae (Penicillin-Non-Susceptible)
          • Haemophilus Influenzae (Ampicillin-Resistant)
          • Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
        • Saudi Arabia Antibiotic Resistance Market, by Drug Class
          • Oxazolidinones
          • Lipoglycopeptides
          • Tetracyclines
          • Cephalosporins
          • Combination
          • Others
      • Turkey
        • Turkey Antibiotic Resistance Market, by Disease
          • Complicated Urinary Tract Infection (cUTI)
          • Complicated Intra-Abdominal Infections (cIAI)
          • Blood Stream Infections (BSI)
          • Clostridium difficile infections (CDI)
          • Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
          • Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
          • Community Acquired Bacterial Pneumonia (CABP)
        • Turkey Antibiotic Resistance Market, by Pathogen
          • Acinetobacter baumannii (Carbapenem-Resistant)
          • Staphylococcus Aureus (Methicillin-Resistant)
          • Pseudomonas aeruginosa (Carbapenem-Resistant)
          • E. coli/K. pneumoniae (Carbapenem-Resistant)
          • Enterococcus faecium (Vancomycin-Resistant)
          • Streptococcus pneumoniae (Penicillin-Non-Susceptible)
          • Haemophilus Influenzae (Ampicillin-Resistant)
          • Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
        • Turkey Antibiotic Resistance Market, by Drug Class
          • Oxazolidinones
          • Lipoglycopeptides
          • Tetracyclines
          • Cephalosporins
          • Combination
          • Others
      • U.A.E.
        • U.A.E. Antibiotic Resistance Market, by Disease
          • Complicated Urinary Tract Infection (cUTI)
          • Complicated Intra-Abdominal Infections (cIAI)
          • Blood Stream Infections (BSI)
          • Clostridium difficile infections (CDI)
          • Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
          • Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
          • Community Acquired Bacterial Pneumonia (CABP)
        • U.A.E. Antibiotic Resistance Market, by Pathogen
          • Acinetobacter baumannii (Carbapenem-Resistant)
          • Staphylococcus Aureus (Methicillin-Resistant)
          • Pseudomonas aeruginosa (Carbapenem-Resistant)
          • E. coli/K. pneumoniae (Carbapenem-Resistant)
          • Enterococcus faecium (Vancomycin-Resistant)
          • Streptococcus pneumoniae (Penicillin-Non-Susceptible)
          • Haemophilus Influenzae (Ampicillin-Resistant)
          • Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
        • U.A.E. Antibiotic Resistance Market, by Drug Class
          • Oxazolidinones
          • Lipoglycopeptides
          • Tetracyclines
          • Cephalosporins
          • Combination
          • Others

Report content

Qualitative Analysis

  • Industry overview
  • Industry trends
  • Market drivers and restraints
  • Market size
  • Growth prospects
  • Porter’s analysis
  • PESTEL analysis
  • Key market opportunities prioritized
  • Competitive landscape
    • Company overview
    • Financial performance
    • Product benchmarking
    • Latest strategic developments

Quantitative Analysis

  • Market size, estimates, and forecast from 2014 to 2025
  • Market estimates and forecast for product segments up to 2025
  • Regional market size and forecast for product segments up to 2025
  • Market estimates and forecast for application segments up to 2025
  • Regional market size and forecast for application segments up to 2025
  • Company financial performance
What questions do you have? Get quick response from our industry experts. Request a Free Consultation
gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon D&B icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.